李美玲
赣南医科大学第一临床医学院
摘要(Abstract):
炎症性肠病(Inflammatory boweldisease,IBD)主要包括溃疡性结肠炎(Ulcerative colitis,UC)和克罗恩病(Crohn's disease,CD),是一种慢性非特异性炎症。目前为止,尚无诊断及监测IBD的金标准。内窥镜检查、影像学检查、组织学检查是提供有关疾病状态、位置和严重程度信息的基本诊断工具。然而,由于内窥镜为侵入性检测且成本高昂,不适合频繁监测IBD患者的疾病活动,无创生物标志物的出现为IBD诊断及病情长程监测提供可能性。目前可用的基于血液和粪便的生物标志物提供了可重复使用的定量工具,可以补充临床评估,帮助临床医师诊断和治疗IBD。基因组和微生物组技术的进步促进了IBD新型生物标志物的开发。本文综述了目前新兴的生物标志物,介绍了IBD生物标志物的最新进展及挑战。
关键词(KeyWords):
炎症性肠病;无创生物标志物;诊断;抗整合素αvβ6抗体;肠道微生物
参考文献(References):
[1]Takeshi K ,Masahiro S ,Yuzo K , et al.Identification of an Anti-Integrin α v β 6 Autoantibody in Patients With Ulcerative Colitis.[J].Gastroenterology,2021,160(7):2383-2394.e21.
[2] Okabe M ,Yamamoto S ,Shiokawa M , et al.Publisher Correction: Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study[J].Journal of Gastroenterology,2024,60(2):1-2.
[3] Pertsinidou E , Salomon B , Bergemalm D , et al.Anti-integrin α v β6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype[. J].Journal of Crohn's & colitis, 2025.
[4]Yasuda M ,Shiokawa M ,Kuwada T ,et al.Anti-integrin α v β 6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.[J].Journal of gastroenterology,2024,60(1):1-9.
[5] Zhuang X ,Jiang H ,Fan T , et al.Serum regenerative islet-derived protein 1 α : a novel and sensitive biomarker for endoscopic disease activity in ulcerative colitis. [J]. Annals of medicine,2025,57(1):2496404.
[6] Tratenšek A ,Locatelli I ,Grabnar I , et al.Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activity: A systematic review and meta-analysis [J].Redox Biology,2024,77103380-103380.
[7]Bourgonje R A ,Gabriëls Y R ,Borst D H M ,et al.Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease [J].Antioxidants,2019,8(9):351-351.
[8]Bohra A ,Batt N ,Dutt K , et al.Prospective Evaluation of Serum Free Thiols in Inflammatory Bowel Disease: A Candidate to Replace C-Reactive Protein for Disease Activity Assessment? [J].Inflammatory bowel diseases,2024.
[9]Dotan I ,Fishman S ,Dgani Y ,et al.Antibodies Against Laminaribioside and Chitobioside Are Novel Serologic Markers in Crohn’s Disease[J].Gastroenterology,2006,131(2):366-378.
[10]D T ,T S L ,D M ,et al.Faecal calprotectin,lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response.[J].Gut,2010,59(9):1207-12.
[11]Almousa A A ,Morris M ,Fowler S , et al.Elevation of s in ed ru icm esp [ yrJu] v .aC te lin k i icn a a lseBi M oc2 h ( em PK isM try 2, )i 2 n 0 I 1 B 8 D, a5 n 3 d 19 its2 r4 el .ationship to IBD
[12]Huss M ,Elger T ,Kunst C ,et al.Fecal Arachidonic Acid: A Potential Biomarker for Inflammatory Bowel Disease Severity [ J ] .International Journal of Molecular Sciences , 2025 , 26 (9):4034-4034.
[13] Roberto T ,Kai Z ,Natasha K , et al.Fecal Leukocyte Esterase , an Alternative Biomarker to Fecal Calprotectin in Inflammatory Bowel Disease: A Pilot Series[J].Gastro Hep Advances, 2022,1(1):45-51.
[14] Zheng J , Sun Q , Zhang M ,et al.Noninvasive, microbiome-based diagnosis of inflammatory bowel disease[J].Nature Medicine[2025-10-31].
[15]Belete A M ,Tadesse S ,Tilahun M ,et al.Long noncoding RNAs and circular RNAs as potential diagnostic biomarkers of inflammatory bowel diseases: a systematic review and meta-analysis [J].Frontiers in Immunology,2024,151362437-1362437.